Results Page

There are many treatment options for chronic lung conditions. However, many of them are medications that mask the symptoms of the condition. We provide potential patients with the facts they need to make an informed choice. We disclose information about our treatment outcomes and patient experiences to ensure the highest level of transparency for our patients. We hope the findings below will help you make the right treatment choice for yourself.

Positive Quality of Life Patient Outcomes for COPD at 3 Months*
From June 02, 2014 to October 18, 2018 a total of 2,008 COPD patients were evaluated for 3-month post-treatment breathing outcomes with the Clinical COPD Questionnaire (CCQ). The CCQ is a self-report tool used to evaluate the patient perspective of quality of life in three areas:

  • Symptoms, such as coughing and phlegm production
  • Mental status, such as anxiety and depression
  • Functional status, such as activity tolerance

75% had significant improvement
16.6% maintained their breathing status and did not decline.
(91.6% overall) 

Positive Quality of Life Patient Outcomes for COPD at 1 Year*
The same group of patients were surveyed again for 12-month post-treatment breathing outcomes with the Clinical COPD Questionnaire (CCQ).  754 patients responded to the survey.

64.1% had significant improvement
22.5% maintained their breathing status and did not decline.
(86.6% overall)

Melissa M. Rubio (2019) Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease. J Clin Res Med Volume 2(4): 1–8.
In 2020, 626 additional patients were surveyed for 12-month post-treatment breathing outcomes with the Clinical COPD Questionnaire (CCQ).

64.9% had significant improvement
21.7% maintained their breathing status and did not decline.
(86.6% overall)

Melissa M. Rubio (2020) Longitudinal Effectiveness of Cellular-Based Therapy in COPD Compared with the Standard of Care.  Am J Respir Crit Care Med 2020;201:A4290

 
Positive Patient Outcomes for Interstitial Lung Disease and Pulmonary Fibrosis at 3 Months*
From June 02, 2014 to October 18, 2018 a total of 399 ILD/PF patients were evaluated for 3-month post-treatment breathing outcomes with the Clinical COPD Questionnaire (CCQ). The CCQ is a self-report tool used to evaluate the patient perspective of quality of life in three areas:

  • Symptoms, such as coughing and phlegm production
  • Mental status, such as anxiety and depression
  • Functional status, such as activity tolerance

The CCQ is widely used to assess breathing-related quality of life in patients with interstitial lung disease and pulmonary fibrosis, as well as other chronic lung diseases. 

66.2% had significant improvement
21.8% maintained stasis and did not decline.
(88% Overall)

 

Positive Patient Outcomes for Interstitial Lung Disease and Pulmonary Fibrosis at 12 Months*
From June 02, 2014 to October 18, 2018 a total of 399 ILD/PF patients were evaluated for 12-month post-treatment breathing outcomes with the Clinical COPD Questionnaire (CCQ). The CCQ is a self-report tool used to evaluate the patient perspective of quality of life in three areas:

  • Symptoms, such as coughing and phlegm production
  • Mental status, such as anxiety and depression
  • Functional status, such as activity tolerance

 

47.6% had significant improvement
24.4% maintained their breathing status and did not decline.
(72% overall)

Patient Testimonials
The patients offering statements about their treatments with Lung Health Institute were not paid to do so. Their opinions are their own statements and do not reflect the opinions of Lung Health Institute.